MARC details
000 -LEADER |
fixed length control field |
03207nam a22006257a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
200210s20202020 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
1878-0938 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1016/j.carrev.2019.12.039 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
S1553-8389(20)30009-9 [pii] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
31952919 |
245 ## - TITLE STATEMENT |
Title |
The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: A review of current evidence. [Review] |
251 ## - Source |
Source |
Cardiovascular Revascularization Medicine. 21(4):540-548, 2020 04. |
252 ## - Abbreviated Source |
Abbreviated source |
Cardiovasc Revasc Med. 21(4):540-548, 2020 04. |
252 ## - Abbreviated Source |
Former abbreviated source |
Cardiovasc Revasc Med. 2020 Jan 07 |
253 ## - Journal Name |
Journal name |
Cardiovascular revascularization medicine : including molecular interventions |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2020 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2020 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
aheadofprint |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
ppublish |
266 ## - Date added to catalog |
Date added to catalog |
2020-02-10 |
268 ## - Previous citation |
-- |
Cardiovascular Revascularization Medicine. 2020 Jan 07 |
501 ## - WITH NOTE |
Local holdings |
Available in print through MWHC library: 2002 - present |
520 ## - SUMMARY, ETC. |
Abstract |
Advances in stent design and the development of bioresorbable polymers have allowed the development of novel stent technologies such as the Orsiro bioresorbable-polymer sirolimus eluting stent (BP-SES). Over several noninferiority trials, the BP-SES has demonstrated itself to be a safe and effective therapy for obstructive coronary artery disease. This article reviews the current evidence of the efficacy of the BP-SES and examines its performance in high-risk populations, such as patients presenting with ST-segment myocardial infarction, chronic total occlusions, diabetes, and small vessel disease. Copyright (c) 2020 Elsevier Inc. All rights reserved. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Absorbable Implants |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Acute Coronary Syndrome/th [Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Cardiovascular Agents/ad [Administration & Dosage] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Coronary Artery Disease/th [Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Drug-Eluting Stents |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Percutaneous Coronary Intervention/is [Instrumentation] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Sirolimus/ad [Administration & Dosage] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Acute Coronary Syndrome/dg [Diagnostic Imaging] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cardiovascular Agents/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Coronary Artery Disease/dg [Diagnostic Imaging] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Percutaneous Coronary Intervention/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prosthesis Design |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Risk Factors |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Sirolimus/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Time Factors |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Treatment Outcome |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Heart & Vascular Instituteon |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Review |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Case, Brian C |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Forrestal, Brian J |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Garcia-Garcia, Hector M |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Waksman, Ron |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Yerasi, Charan |
790 ## - Authors |
All authors |
Case BC, Forrestal BJ, Garcia-Garcia HM, Waksman R, Yerasi C |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1016/j.carrev.2019.12.039">https://dx.doi.org/10.1016/j.carrev.2019.12.039</a> |
Public note |
https://dx.doi.org/10.1016/j.carrev.2019.12.039 |
-- |
https://dx.doi.org/10.1016/j.carrev.2019.12.039 |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1016/j.carrev.2019.12.039">https://dx.doi.org/10.1016/j.carrev.2019.12.039</a> |
Public note |
https://dx.doi.org/10.1016/j.carrev.2019.12.039 |
-- |
https://dx.doi.org/10.1016/j.carrev.2019.12.039 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |